FindTrial
Sign In

Treatment Efficacy and Outcome of treatment of Sofosbuvir/Velpatasvir in Hepatitis C Virus Infection Among Adolescents and Young Adults

Treatment Efficacy and Outcome of treatment of Sofosbuvir/Velpatasvir in Hepatitis C Virus Infection Among Adolescents and Young Adults

Status
Unknown
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230610001
Enrollment
35
Registered
2023-06-10
Start date
2023-07-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adolescents and young adults who have hepatitis C virus infection Hepatitis C virus, adolescents, young adults, sofosbuvir/velpatasvir, efficacy, treatment outcome

Interventions

adolescents and young adults with positive serum HCV RNA
Treatment
HCV infection

Sponsors

Research and Developmeny Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 26 Years

Inclusion criteria

Inclusion criteria: - Aged 13-26 years - Body weight > 30 kg - Positive HCV RNA

Exclusion criteria

Exclusion criteria: - History of HCV infection with ever-treated - Pregnant woman - Uncontrollable underlying disease, e.g., HIV-infected patient who started ARV <  1 month or has an opportunistic infection - Significant fibrosis: AST to Platelet Ratio Index (APRI) > 0.5

Design outcomes

Primary

MeasureTime frame
treatment efficacy at 24 months after start treatment Serum HCV RNA—

Secondary

MeasureTime frame
treatment outcome and adverse event at 6,12,24 weeks after start treatment by interviews—

Countries

Thailand

Contacts

Public ContactThanyawee Puthanakit

Faculty of Medicine,Chulalongkorn University

thanyawee.p@chula.ac.th66896658846

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026